Bayer lifts earnings guidance on strong nine-month performance in pharma

Bayer AG raised its full-year EBITDA forecast to €9.8–10.3 billion following strong pharmaceutical performance, despite a widened Q3 net loss of €678 million. Sales grew 4.1% year-over-year, driven by pharma growth while crop science faced headwinds.